All acquired results initially supported the inference that dysregulated functionomes with active DEGs and relevant biomarkers could cooperate with the dysfunctional AHR binding pathway together with increased EMT effects in the tumor microenvironment to synergistically influence tumor initiation. The gene discussed is AHR; the disease is neoplasm.